Related Experiment Videos
Endotracheal tolazoline administration in neonates with persistent pulmonary hypertension
1Division of Neonatology, University of Kentucky Medical Center, Lexington, USA.
Insights
Endotracheal tolazoline (ET-Tz) effectively improved oxygenation in neonates with persistent pulmonary hypertension (PPHN). This treatment was particularly beneficial for sick preterm infants, offering a safe alternative to other methods.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Pharmacology
Background:
- Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition.
- Effective treatment strategies for PPHN are crucial for improving neonatal outcomes.
Purpose of the Study:
- To evaluate the efficacy of endotracheal tolazoline (ET-Tz) in treating neonatal PPHN.
- To assess the safety and effectiveness of the endotracheal route for tolazoline administration.
Main Methods:
- Twelve neonates diagnosed with PPHN received ET-Tz.
- Tolazoline dosage ranged from 1 to 2.5 mg/kg.
- Infants included a wide range of gestational ages (25-42 weeks) and birth weights (850-3612 gm).
Main Results:
- Significant improvements in oxygen saturation and arterial oxygen tension were observed post-treatment (p < 0.005).
- A significant decrease in the oxygenation index was noted (p < 0.005).
- Arterial carbon dioxide tension remained unchanged; preterm infants showed significantly different responses compared to term infants (p < 0.001).
Conclusions:
- ET-Tz demonstrates effectiveness in enhancing oxygenation for neonates with PPHN.
- The endotracheal route is advantageous due to a lack of significant side effects like hypotension or flushing.
- Further investigation via a randomized, controlled, double-blinded, multicenter trial is recommended.
Objectives:
Our purpose was to study the effectiveness of endotracheal tolazoline (ET-Tz) in the treatment of neonatal persistent pulmonary hypertension (PPHN).
Study Design:
ET-Tz was administered to 12 neonates with a clinical diagnosis of PPHN. The gestational age ranged from 25 to 42 weeks, and the birth weights from 850 to 3612 gm. The dose of tolazoline ranged from 1 to 2.5 mg/kg.
Results:
There was a significant increase (p < 0.005) in the mean levels of oxygen saturation and the arterial oxygen tension, and a significant decrease (p < 0.005) in the oxygenation index, between the pretolazoline and the posttolazoline groups, but arterial carbon dioxide tension did not change. After the initial analysis, the groups were subdivided into preterm and term subgroups, because we secondarily observed that the average changes from predose to postdose levels in the above parameters were significantly different (p < 0.001) in the two subgroups by Student's paired t test.
Conclusions:
The data indicate that ET-Tz is effective in improving oxygenation in neonates with PPHN, particularly sick preterm infants. The endotracheal route is preferred because it is devoid of significant side effects (e.g., hypotension and flushing). A randomized, controlled, double-blinded, multicenter trial for the use of ET-Tz in PPHN is warranted.